Tetra Bio-Pharma Inc. (JAM1.F)
Chart Events
Performance Outlook
| Previous Close | 0.0289 |
| Open | 0.0279 |
| Bid | 0.0200 x 4074100 |
| Ask | 0.0358 x 2558200 |
| Day's Range | 0.0201 - 0.0279 |
| 52 Week Range | 0.0046 - 0.0942 |
| Volume | |
| Avg. Volume | 7,565 |
| Market Cap | 8.51M |
| Beta (5Y Monthly) | 2.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for JAM1.F
Related Research
- CNW Group
REDUVO™ Marketing Approval on the Right Path
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with another regulatory update on the REDUVO™ New Drug Submission (NDS). The last update was provided on November 18, 2022.
- CNW Group
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclin
- ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Group Eleven, iMining, Gamelancer, Cassiar Gold, ApartmentLove, Tetra Bio-Pharma and Sitka Gold Discussing Their Latest News
The Power Play by The Market Herald has announced the release of new interviews with Group Eleven, iMining, Gamelancer, Cassiar Gold, ApartmentLove, Tetra Bio-Pharma and Sitka Gold discussing their latest news.
